Euclidean Capital’s Vir Biotechnology VIR Stock Holding History

Euclidean Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-40,257	Closed	-$1.69M	–	13
2021 Q4	$1.69M	Buy	+40,257	New	+$1.58M	0.96%	11
2021 Q3	–	Sell	-25,866	Closed	-$1.22M	–	15
2021 Q2	$1.22M	Buy	25,866 +2	+0%	+$91	0.4%	14
2021 Q1	$1.33M	Buy	+25,864	New	+$1.39M	0.44%	11

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Euclidean Capital's VIR Position: Q1 2022 in Review

Euclidean Capital sold out of Vir Biotechnology (VIR) in Q1 2022, closing a stake of 40,257 shares — an estimated $1.69M sold.

Euclidean Capital first reported a position in VIR in Q1 2021 and held it in 3 quarters. The position peaked at $1.69M in Q4 2021. 204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

Euclidean Capital reported no remaining Vir Biotechnology position as of Q1 2022 after selling out during the quarter.
Euclidean Capital sold 40,257 Vir Biotechnology shares in Q1 2022, an estimated $1.69M.
Euclidean Capital first reported a position in Vir Biotechnology in Q1 2021 and held it in 3 quarters.
Euclidean Capital's Vir Biotechnology position peaked at $1.69M in Q4 2021.
204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Euclidean Capital's 13F filing for Q1 2022, filed 16 May 2022.